

A practical guide for ophthalmologists and prescribers to help patients find Bromfenac in stock, reduce delays, and navigate alternatives in 2026.
When a cataract surgery patient calls your office the day after their procedure saying the pharmacy can't fill their Bromfenac prescription, it creates a clinical problem and an administrative headache. Post-operative inflammation management shouldn't wait, and neither should your patients.
This guide provides a practical, actionable framework for ophthalmology practices and prescribers to proactively manage Bromfenac access for their surgical patients — from pre-operative planning through post-operative follow-up.
As of 2026, Bromfenac is available in three forms in the US market:
Bromfenac is not on formal shortage lists (FDA or ASHP), but real-world availability is inconsistent. The root cause is low pharmacy inventory for a niche, short-course ophthalmic medication — not a manufacturing shortage.
For the full supply chain background, see our provider shortage briefing.
Understanding the bottlenecks helps you design better workflows:
The single most impactful change is transmitting the Bromfenac prescription 3-5 days before the scheduled surgery date. This gives the pharmacy time to:
Build this into your pre-surgical workflow as a standard step, not an afterthought.
Use Medfinder for Providers to check real-time Bromfenac availability at your patient's preferred pharmacy. If the pharmacy doesn't have it, you can redirect the prescription to one that does — while the patient is still in your office.
This one step eliminates the most common complaint: "My pharmacy doesn't have it and I don't know what to do."
Have alternative prescriptions prepared for situations where Bromfenac is unavailable. Your pre-printed or templated alternatives should include:
Discuss with patients upfront that if their pharmacy can't fill Bromfenac, you have an approved backup plan. This reduces anxiety and prevents delays.
Many patients don't know that discount cards can dramatically reduce the cost of generic Bromfenac. Provide a brief handout or direct patients to our savings guide that covers:
Establish a relationship with 1-2 pharmacies that reliably stock Bromfenac — ideally independent pharmacies near your practice. Benefits include:
Some practices negotiate with a nearby pharmacy to maintain a minimum stock level of post-surgical drops based on their surgery schedule.
When switching a patient from Bromfenac, consider these evidence-based alternatives:
| Drug | Concentration | Dosing | Approx. Cost (with coupon) |
|---|---|---|---|
| Ketorolac (Acular) | 0.5% | 1 drop QID × 14 days | $15-$40 |
| Nepafenac (Ilevro) | 0.3% | 1 drop QD × 14 days | $80-$200 (brand) |
| Nepafenac (Nevanac) | 0.1% | 1 drop TID × 14 days | $40-$80 (generic) |
| Diclofenac | 0.1% | 1 drop QID × 14 days | $15-$30 |
| Flurbiprofen (Ocufen) | 0.03% | Intraoperative use | $20-$50 |
All alternatives share the same NSAID mechanism (COX inhibition) and are effective for post-cataract inflammation. The primary tradeoffs are dosing frequency, cost, and specific vehicle characteristics.
For a patient-facing resource, direct patients to: Alternatives to Bromfenac.
Bromfenac access challenges are solvable with the right workflow adjustments. By prescribing early, verifying stock proactively, maintaining backup alternatives, and educating patients on cost options, your practice can virtually eliminate post-surgical prescription delays.
Visit Medfinder for Providers to start checking real-time pharmacy availability for your patients today. For more on the current supply landscape, read our Bromfenac shortage briefing for providers.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.